Module

Clinical Potential of Novel Cytotoxic and Biologic Agents in Ovarian Cancer

Source: Managing Ovarian Cancer Recurrence: Coupling Novel Therapeutics With Optimal Treatment Decisions

Clinical Potential of Novel Cytotoxic and Biologic Agents in Ovarian Cancer

Faculty:

Robert A. Burger, MD
Leslie Randall-Whitis, MD

CME CREDIT INFORMATION

Release Date: 09/19/08

Expiration Date: 09/18/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Cite ongoing clinical trials of novel cytotoxic and biologic agents used in the treatment of ovarian cancer
Describe recent results from clinical trials of cytotoxic and biologic agents used to treat ovarian cancer
Discuss novel agents used to treat patients with ovarian cancer

Topics covered include:

Introduction
The GOG Ovarian Cancer Phase II Program
Novel Cytotoxic Agents for the Treatment of Ovarian Cancer
Resistance-Modifying Agents for the Treatment of Ovarian Cancer
Monoclonal Antibodies for the Treatment of Ovarian Cancer
Future Potential of Biologic and Targeted Therapies

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.